Excelitas Technologies introduces multi-wavelength illumination system


Excelitas Technologies, a global technology leader focused on delivering innovative, customized photonic solutions, adds X-Cite Vitae vIR to its popular X-Cite fluorescence illuminator product line. X-Cite Vitae vIR is a customizable, multi-wavelength illumination system designed for high precision medical illumination and diagnostic applications.

The X-Cite Vitae vIR provides versatile, high-performance illumination for color-sensitive applications, including surgical endoscopy. Designed to replace traditional 180W or 300W xenon sources, this high brightness, solid-state white light source features adjustable color temperature and repeatable output in an easily-integrative turnkey system. X-Cite Vitae vIR offers a unique capability to shape the spectrum in accordance with the camera being used to obtain the desired color temperature in an image for accurate diagnosis.

With up to six high-power wavelengths (400-410nm, 450-460nm, 500-600nm, 625-640nm, and 780-790nm), ranging from visible to IR, the X-Cite Vitae vIR offers maximum flexibility for fluorescence excitation in applications such as endoscopy and surgical visualization. Wavelengths can be customized according to application and controlled in any combination or individually; it has a tunable correlated color temperature (CCT) for RGB white configuration and spectral shaping for high color rendering index (CRI). The system can be tailored with feedback sensors to monitor output wavelength.

Multiple control options include manual on/off and intensity control, with 1% increments for each color; USB control, RS232 control and I/O connectivity. TTL input is available for on/off control with 2.4V-5V TTL compatibility. Analog I/O intensity control is also available. Footprint, controls, wavelength, and spectrum can all be customized to suit a customer’s particular device design and application requirements.

How do you know your technology is disruptive enough to break conventional wisdom?

textadimage Stan Rowe knows a little something about bringing disruptive technology to market. The current Edwards Lifesciences CSO was in on the ground floor of two of medtech's most disruptive treatments, stents and transcatheter aortic valve replacement.

On December 12th, Rowe will sit down with MassDevice editor Brad Perriello for a long ranging discussion about the inside story on how these technologies came to market and what Rowe learned along the way.

Register now with the code "TAVR" and save 15% today.

Speak Your Mind